Clovis Oncology to seek FDA approval for ovarian cancer drug as a maintenance therapy


Shares of Clovis Oncology Inc. CLVS, -3.51% soared 40.0% in premarket trading on Thursday after the company said its drug, Rubraca, improved survival when used as a maintenance treatment for women with ovarian cancer. The data comes from a double-blind, placebo-controlled, Phase 3 clinical trial that enrolled 538 women. Clovis said it plans to seek approval for Rubraca in the E.U. and the U.S. this year as first-line maintenance treatment for women with advanced ovarian cancer regardless of their biomarker status and who have already responded to chemotherapy. Rubraca is already approved as a third-line treatment in BRCA-mutated ovarian cancer. Clovis shares are down 39.1% this year, while the broader S&P 500 SPX, -0.63% has declined 3.4%.

This article was originally published by Read the original article here.

Previous article: How to make your money last in retirement
Next articleNew gender marker to be available on U.S. passports


Please enter your comment!
Please enter your name here